NCT01357902View on ClinicalTrials.gov

Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 18, 2011

Primary Completion Date

May 23, 2011

Study Completion Date

May 23, 2011

Conditions
Epilepsy
Interventions
DRUG

Lamotrigine

Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.

Trial Locations (1)

Unknown

GSK Investigational Site, Shatin, New Territories

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01357902 - Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China | Biotech Hunter | Biotech Hunter